National Comprehensive Cancer Network

The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
The updated guidelines from the National Comprehensive Cancer Network on the management of breast expand treatment options in HER2-positive disease to include extended adjuvant neratinib after completion of trastuzumab in patients with high risk of recurrence and recognize a third CDK 4/6 inhibitor in hormone-sensitive breast cancer.
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.

Results 1 - 6 of 6

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code